TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26434651
Drug: Adjunctive full-mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive full-mouth intensive removal of subgingival dental plaque biofilms with scaling and root planning (group 2)
Study: 25082595
Drug: Granisetron (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (40 μg/kg)
Study: 20362507
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg intravenously every 3 weeks for 1 year)
Study: 17327378
Drug: PPARgamma agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPARgamma agonist (rosiglitazone)
Study: 17327378
Drug: PPARalpha agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPARalpha agonist (fenofibrate)
Study: 17327378
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metyrapone and RU38486 (glucocorticoid blockade)
Study: 12395217
Drug: Water dispersible
Normalized name: GNP Vitamin E 400units Water Dispersible Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water dispersible beta-carotene powder (7.2 mg/d)
Study: 12395217
Drug: Water dispersible
Normalized name: GNP Vitamin E 400units Water Dispersible Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water dispersible beta-carotene powder (21.6 mg/d)
Study: 12395217
Drug: Carrot juice-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot juice-based drink (6 mg/d)
Study: 12395217
Drug: Carrot juice-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot juice-based drink (18 mg/d)
Study: 10219465
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose benfotiamine (4 x 2 capsules/day, = 320 mg benfotiamine/day)
Study: 10219465
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose benfotiamine (3 x 1 capsules/day)
Study: 10219465
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with benfotiamine (3 x 1 tablets/day, = 150 mg benfotiamine/day)
Study: 7727315
Drug: 5-fluorouracil (5-FU),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (5-FU), 700 mg/m2
Study: 7273700
Drug: Doxepin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (100 mg)
Study: 9088587
Drug: Desipramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (100 mg)
Study: 7273700
Drug: Nortriptyline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (100 mg)
Study: 6303673
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg in the morning and placebo in the evening (Group I)
Study: 6303673
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg twice daily (Group II)
Study: 17581320
Drug: Conventional-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose hormone therapy
Study: 17581320
Drug: Low-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormone therapy
Study: 30507711
Drug: Conventional-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose hormone therapy (in women with a history of venous thrombosis)
Study: 27806355
Drug: Lowering dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering dialysate calcium concentration to 1.25 mmol/l
Study: 27806355
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with dialysate calcium concentration at 1.5 mmol/l
Study: 25372006
Drug: home-based modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: home-based modified constraint-induced movement therapy (mCIMT)
Study: 15510184
Drug: Apomorphine SL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine SL (3 mg, four tablets)
Study: 30248365
Drug: Taurine (TAU)
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine (TAU) supplementation, single dose, dosage not specified
Study: 21293156
Drug: ACEi and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEi and/or ARB therapy; 94% of patients had prior therapy with ACEi and/or ARB at the time of screening.
Study: 12825328
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Con, n = 7) maintained usual daily activities
Study: 10479220
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose to years of treatment
Study: 7741542
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (50 micrograms/g) applied twice daily for up to 12 weeks
Study: 7741542
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle of calcipotriol ointment)
Study: 2202789
Drug: Postoperative fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative fluorouracil (5‐FU) and heparin administered via the portal vein
Study: 2202789
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment following curative resection
Study: 7275458
Drug: 80 kcal
Normalized name: glucose polymers 380 kcal/100 gram ORAL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kcal VLCD (17 g protein)
Study: 7275458
Drug: 180 kcal
Normalized name: long chain triglycerides 20 gram-180 kcal/100 mL ORAL EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 kcal VLCD (40 g protein)
Study: 7275458
Drug: Mixed VLCD
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed VLCD (80 kcal for 1st and 2nd week, 180 kcal with 17 g protein + 25.5 g CHO for 3rd and 4th week)
Study: 29439395
Drug: Probiotic-mixture (Vivomixx®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic-mixture (Vivomixx®, Visbiome®, DeSimone Formulation®)
Study: 23911209
Drug: Intraoperative regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative regional cerebral oxygen saturation (rSO2) monitoring with active display and Murkin treatment intervention protocol
Study: 22093485
Drug: Intensive dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive dietary therapy (dietary advice six times during pregnancy)
Study: 22093485
Drug: Intensive dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive dietary therapy
Study: 19934619
Drug: Elevated parathyroid
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elevated parathyroid hormone (PTH) > or = 62 ng/L (IV-quartile)
Study: 15673874
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 40 mg IM and IV lidocaine 3 mg . kg(‐1) . h(‐1) (group DM+L)
Study: 15673874
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 40 mg IM (group DM)
Study: 15673874
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine 3 mg . kg(‐1) . h(‐1) (group L)
Study: 15673874
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (CPM) 20 mg IM and IV normal saline (N/S) (group C)
Study: 11800105
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using infrared diode laser (GaAlAs) 830 nm continuous wave and HeNe 632.8 nm combined with diode laser 904‐nm pulsed wave
Study: 8649560
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange (PE) combined with azathioprine 2 mg/kg, performed once a week for 4 weeks and thereafter every second week for 20 weeks (14 treatments)
Study: 8649560
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange (PE) combined with azathioprine 2 mg/kg
Study: 30178484
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n=6)
Study: 22526196
Drug: QUIXIL® fibrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: QUIXIL® fibrin sealant (2 ml)
Study: 8150760
Drug: Cefepime 1
Normalized name: cefepime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 1 g bd
Study: 3529375
Drug: Weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly low-dose methotrexate (Mtx)
Study: 31502272
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (parenteral plus enteral; total 400 mg/kg/d)
Study: 29287668
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of Integrated Posttraumatic Stress and Substance Use (TIPSS)
Study: 29287668
Drug: Standard cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive-behavioral treatment (CBT) for SUD
Study: 23731573
Drug: N-acetylcysteine (6000
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (6000 mg iv one hour before contrast CT)
Study: 3311923
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (160 mg/day)
Study: 7970508
Drug: Other hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Other hormonal treatments
Study: 22584558
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus followed by a 2 mg/kg/h infusion until the end of the surgical procedure)
Study: 20857058
Drug: 25 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g/day of soy
Study: 20857058
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of n‐3 fatty acids (fish oil)
Study: 20857058
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of n‐3 fatty acids (fish oil) and 25 g/day of soy
Study: 29906601
Drug: SOF (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF (400 mg once daily) + DCV (60 mg once daily)
Study: 29906601
Drug: SOF (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF (400 mg once daily) + SMV (150 mg once daily)
Study: 15459835
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 800 microg salbutamol
Study: 11742431
Drug: Saquinavir-enhancing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir-enhancing therapy (SQV) with stavudine (d4T) and one of ritonavir, nelfinavir, or delavirdine.
Study: 7989960
Drug: HPMC strips
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC strips containing 40% doxycycline, applied twice a week for 6 weeks
Study: 7989960
Drug: MC strips
Normalized name: MC-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC strips containing 40% doxycycline, applied twice a week for 6 weeks
Study: 25873090
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) with booster sessions
Study: 23692061
Drug: PA32540 (EC-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA32540 (EC-ASA 325 mg + IR-omeprazole 40 mg)
Study: 23692061
Drug: Enteric-coated omeprazole
Normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated omeprazole 40 mg
Study: 22260148
Drug: Self-help manual
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help manual along with standard care and treatment
Study: 17587390
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg daily in week 1, 500 mg twice daily in week 2, 1000 mg twice daily in weeks 3 and 4)
Study: 16138267
Drug: glimepiride 1-6
Normalized name: glimepiride 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride 1-6 mg
Study: 9861542
Drug: Estradiol (E)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol (E) infusion (15 ng/kg/hr)
Study: 1280802
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ibuprofen
Study: 8706118
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg acetylsalicylic acid
Study: 16416218
Drug: lansoprazole, amoxicillin,
Normalized name: Lansoprazole, Amoxicillin, Clarithromycin KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole, amoxicillin, and clarithromycin
Study: 15120943
Drug: Standard arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard arm of uniform treatment, 10% of patients from each participating trial.
Study: 2961501
Drug: Dexamethasone 0.1
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1 mg
Study: 2961501
Drug: Dexamethasone 0.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.32 mg
Study: 788430
Drug: Dexamethasone 1.0
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL / DEXAMETHASONE 1.0 mg in 1 mL OPHTHALMIC SUSPENSION/ DROPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1.0 mg
Study: 27370062
Drug: Standard Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Drug Treatment (ST)
Study: 27370062
Drug: Combined Treatment
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Treatment (CBT + ST)
Study: 22509402
Drug: Genotype-based NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-based NRT dosing
Study: 22509402
Drug: Phenotype-based NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenotype-based NRT dosing
Study: 7480228
Drug: Smooth devices
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth devices irrigated with saline solution
Study: 1705432
Drug: Cerulein at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerulein at doses of 0.05, 0.1, 0.2, 0.3, 0.5 microgram/Kg/h
Study: 1705432
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (125 ml/h)
Study: 1705432
Drug: Cerulein (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerulein (various doses)
Study: 7211531
Drug: Contingent reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingent reinforcement for morphine-free urinalysis results
Study: 31892662
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (two oral boluses of 100,000 IU vitamin D3 with 400 IU vitamin D3 daily)
Study: 31892662
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical placebo boluses with daily placebo)
Study: 24456624
Drug: Arm C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm C: Control group (no injections)
Study: 22709460
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 220 mg once daily
Study: 22709460
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150 mg once daily
Study: 15834756
Drug: GLV with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLV with more oil (100 g GLV/day + 5 g oil/day)
Study: 15834756
Drug: GLV with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLV with vitamin E (100 mg/day)
Study: 15834756
Drug: Beta-carotene without
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene without GLV (10 mg/day)
Study: 11593611
Drug: Traditional herb
Normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional herb medicines
Study: 8532025
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of epoprostenol
Study: 1676368
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day tertatolol (T)
Study: 1676368
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day nadolol (N)
Study: 6344196
Drug: Griseofulvin treatment
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin treatment
Study: 9376241
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous analgesia
Study: 22186668
Drug: Carbidopa‐levodopa administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa‐levodopa administration
Study: 17574929
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg/day, n=25)
Study: 9674467
Drug: Adenosine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (maximum dose, 0.05 mg/kg/min)
Study: 9674467
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P (maximum dose, 100 pmol/min)
Study: 8568008
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg daily for 13 days
Study: 2152777
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber (20 mg corn fiber in 4 cookies daily)
Study: 25288
Drug: Triazolam 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.6 mg
Study: 19202451
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy or antiviral prophylaxis (valacyclovir or ganciclovir) for 3 months in 60 patients
Study: 19202451
Drug: CMV viremia
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV viremia with viral load of more than or equal to 2000 copies/mL
Study: 16545748
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with antiepileptic drugs
Study: 16545748
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with antiepileptic drugs
Study: 10932338
Drug: Ava Neb
Normalized name: AVA-6000
DrugBank: AVA-6000 (DB17398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ava Neb 1780 (output 205 +/- 13 mg/min)
Study: 10932338
Drug: Hudson UP
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hudson UP Draft II 1730 (output 356 +/- 31 mg/min)
Study: 6085804
Drug: Polymyxin B/gramicidin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin B/gramicidin ear drop combination at bedtime on the day they swam
Study: 30111683
Drug: Paprika xanthophyll
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paprika xanthophyll capsules (9.0 mg of paprika xanthophylls)
Study: 16304442
Drug: Conventional dentifrice
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional dentifrice (1100 microg F/g) after lunch
Study: 16304442
Drug: Low-fluoride dentifrice
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fluoride dentifrice (550 microg F/g) on fasting
Study: 16304442
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 microg F/g)
Study: 12546171
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (90 mL mixed with 300 mL clear liquid and 4-5 glasses of water)
Study: 12546171
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol solution (2 liters)
Study: 11202131
Drug: Mianserin 60
Normalized name: mianserin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 60 mg/day plus fluoxetine 20 mg/day
Study: 12499712
Drug: Mianserin 60
Normalized name: mianserin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 60 mg/day
Study: 2466056
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of pirmenol
Study: 2466056
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of pirmenol
Study: 2466056
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of pirmenol
Study: 29790382
Drug: Low ventilation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low ventilation (LV, respiratory rate ≤8/minute and tidal volume <500 mL)
Study: 25709404
Drug: Viron (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viron (three tablets twice daily)
Study: 25709404
Drug: Viron (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viron (two tablets twice daily)
Study: 25709404
Drug: Viron (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viron (one tablet twice daily)
Study: 25709404
Drug: Viron (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viron (highest dose)
Study: 17444155
Drug: Terasosine (setegis)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terasosine (setegis) 1 mg twice a day for 2 months
Study: 10966997
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg taken once every 4 weeks
Study: 8864322
Drug: Thyrotrophin releasing
Normalized name: Thyrotrophin releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotrophin releasing hormone (TRH) 50 micrograms
Study: 8864322
Drug: Thyrotrophin releasing
Normalized name: Thyrotrophin releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotrophin releasing hormone (TRH) 200 micrograms
Study: 8864322
Drug: Thyrotrophin releasing
Normalized name: Thyrotrophin releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotrophin releasing hormone (TRH) 500 micrograms